The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1
Abstract
BONE IS permanently turned over by the balanced and coordinated action of bone-resorbing osteoclasts and bone-forming osteoblasts, resulting in continuous renewal, functional response to external and internal stimuli, and structural integrity (1–3). Inappropriate bone resorption caused by enhanced osteoclast formation and activity has been previously implicated in the pathogenesis of many metabolic bone diseases. Strategies to inhibit bone resorption have emerged as potent and promising tools for the prevention and treatment of bone and mineral disorders (1–3). The recent discovery and characterization of a novel cytokine system, the tumor necrosis factor (TNF) ligand family member, receptor activator of nuclear factor-κB ligand (RANKL/OPGL/ODF/TRANCE) (4–7);2 its receptor, receptor activator of nuclear factorκ B (RANK/ODAR) (7); and its soluble (decoy) receptor, osteoprotegerin (OPG/OCIF/TR1) (8–11), has established a novel paradigm of osteoclast biology: RANKL, RANK, and OPG constitute the three essential regulatory components of osteoclast formation, fusion, survival, activation, and apoptosis (12–14). This article3 reviews the molecular aspects of this novel cytokine system and its regulation and modulation by various osteotropic agents. Moreover, we summarize the implications of this cytokine system on the pathogenesis of various bone diseases and discuss the therapeutic potential of OPG in the clinical setting. The TNF ligand family member, osteoprotegerin ligand (OPGL)/osteoclast differentiation factor (ODF) was discovered in 1998 by two groups (4, 5) as the cognate ligand for OPG/osteoclastogenesis inhibitory factor (OCIF) (8, 9). This factor had been identified by the same two groups the year before and was shown to be identical to TNF-related activation-induced cytokine (TRANCE) (6) and receptor activator of nuclear factor-κB ligand (RANKL) (7). RANKL will be the preferred term according to a consensus nomenclature (12). RANKL is a cell-bound polypeptide of 317 amino acids (4, 5) that is cleaved by a protease, TNFα-converting enzyme-like protease (TACE) (15), at position 140 or 145, respectively, to give rise to a shorter soluble ectodomain variant of similar activity (4, 15). The major sources of RANKL production in the bone/bone marrow microenvironment are bone marrow stromal cells, osteoblasts, chondrocytes, mesenchymal cells of the periosteum, osteoclasts, endothelial cells, and T cells (4–7, 16). Detailed analyses of its extraskeletal tissue distribution revealed RANKL messenger ribonucleic acid (mRNA) and protein production in brain, heart, kidney, skeletal muscle, and skin (16). Of note, RANKL production is highest in undifferentiated stromal cells and is greatly reduced once these multipotential mesenchymal cells become terminally committed to the osteoblastic phenotype (17–19). Interestingly, the RANKL gene promoter structure contains both vitamin D and glucocorticoid response elements as well as a binding site for the essential osteoblastic transcription factor, cbfa-1 (20–22). In a series of in vitro experiments, RANKL was consistently shown to stimulate the differentiation, survival, and fusion of osteoclastic precursor cells, to activate mature osteoclasts, and to prolong their life span by inhibiting apoptosis (4, 5, 23–27), thus expanding the pool of active osteoclasts capable of forming resorption lacunae (Fig. 1). In the presence of permissive levels of macrophage colony-stimulating factor (M-CSF), RANKL is both sufficient and necessary for all steps of osteoclast development (28) (Fig. 1). Of note, other factors, such as transforming growth factor-β and PGE2, may cooperate and synergize with RANKL (29, 30), although the precise roles of these factors in osteoclast biology are not well defined. Regulation of osteoclast functions by RANKL, OPG, and RANK. Osteoblastic cells express a cell-bound and a soluble form of RANKL as well as the soluble neutralizing receptor, OPG. RANKL and OPG have opposite effects on osteoclast biology. 1) Multipotential macrophagic lineage cells are stimulated by M-CSF, which binds to its receptor c-fms to proliferate and to become osteoclast precursor cells. 2) Under permissive levels of M-CSF, binding of osteoblast-derived RANKL to the receptor RANK induces differentiation of osteoclast precursors to prefusion osteoclasts. OPG blocks this effect by neutralizing RANKL. 3) Survival and fusion are stimulated by RANKL, a process that yields multinucleated osteoclasts and is modulated by cytokines such as IL-1, TNFα, and IL-6 and is inhibited by OPG. 4) Osteoclasts are activated by RANKL (as well as IL-1, TNFα, and IL-6) and become capable of resorbing bone. This is blocked by OPG. 5) Mature osteoclasts undergo apoptosis, which is induced by OPG and prevented by RANKL. Regulation of osteoclast functions by RANKL, OPG, and RANK. Osteoblastic cells express a cell-bound and a soluble form of RANKL as well as the soluble neutralizing receptor, OPG. RANKL and OPG
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Self-citationSevere osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Cited by
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study
Richards, J., Rivadeneira, F., Inouye, M., Pastinen, T., Soranzo, N., Wilson, S., Andrew, T., Falchi, M., Gwilliam, R., Ahmadi, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60599-1 · Cited by 682
Ritchlin, C. T., Haas-Smith, S. A., Li, P., Hicks, D. G., & Schwarz, E. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16069 · Cited by 616
Jeffcoate, W. J., Game, F., & Cavanagh, P. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67029-8 · Cited by 373
Skeletal and Hormonal Effects of Magnesium Deficiency
Rude, R. K., Singer, F. R., & Gruber, H. E. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719764 · Cited by 285
Metadata
- Authors
- Hofbauer, L. C., & Heufelder, A. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-07
- Volume
- 85
- Issue
- 7
- Pages
- 2355-2363
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2155352301
- Cited by
- 169
- References
- 26
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1. https://app.cochat.ai/papers/10.1210/jcem.85.7.6702
- The paper
- Hofbauer, L. C., & Heufelder, A. E. (2000). The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.85.7.6702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.